title: [Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma].
abstract: The Asian variant of intravascular large B-cell lymphoma (AIVL) is a rare aggressive lymphoma characterized by various clinical symptoms, hemophagocytic syndrome and predominant growth within vessels. We present a 73-year-old man with relapsed AIVL who had been treated with six courses of CHOP regimen. A half year later, he presented with high fever, sweat, dementia and hepatosplenomegaly without lymphadenopathy. A bone marrow biopsy showed prominent hemophagocytosis and immunological staining disclosed an augmented intrasinusal pattern of atypical large lymphocytes characteristic of the CD20+ and CD5+ phenotypes. As salvage therapy, CND-R (rituximab, cladribine, mitoxantrone, dexamethasone) was performed, and the clinical symptoms immediately and dramatically improved. Subsequently, CND-R therapy was repeated every 4 weeks. No serious adverse events were observed with the exception of grade 4 neutropenia and grade 3 thrombocytopenia. After completion of the fifth course, a bone marrow biopsy pathologically confirmed complete remission, leading to termination of this therapy. The patient has remained in remission for more than 15 months. CND-R therapy, which is effective for indolent lymphoma, may be one of the candidates in salvage therapy for relapsed AIVL.
authors.affiliation: Department of Hematology, Japanese Red Cross Nagoya First Hospital.
authors.forename: Akane
authors.initials: A
authors.lastname: Tsujimura
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Yachiyo
authors.initials: Y
authors.lastname: Kuwatsuka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Inamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tokunaga
authors.forename: Taku
authors.initials: T
authors.lastname: Oba
authors.forename: Seitaro
authors.initials: S
authors.lastname: Terakura
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ito
authors.forename: Takuhei
authors.initials: T
authors.lastname: Murase
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kodera
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification / Q000188:drug therapy*; D008297:Male; D012008:Recurrence; D000069283:Rituximab; D016879:Salvage Therapy; D019043:Vascular Neoplasms / Q000145:classification / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D017338:Cladribine; D000069283:Rituximab